Canadian data is current through March 2018. All of the data comes from Health Canada, except for the categories Manufacturer Parent Company and Product Classification.
The Parent Company and the Product Classification were added by ICIJ.
The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Canada.
데이터 추가 비고
원인
A carbapenemase producing enterobacteriacae (cre) reported false susceptible with the carbapenem imipenem. the instrument rapid read (<16 hours) reported imipenem of <4 ?g/ml on a synergies plus negative panel and after overnight incubation imipenem was resistant (>8) by visual examination. this results in a categorical very major error (vme).